Biology
Extracellular Vesicle Crosstalk in Tumor Microenvironments
Quick fact
EVs are so stable in bodily fluids that they can be isolated from a simple blood sample, making them a promising 'liquid biopsy' for cancer detection and monitoring.
Why this is interesting
Every second, your cells release millions of microscopic packages that act as messengers. But what if those messengers are being hijacked to set the stage for cancer's invasion?
Read the full explanation
Understanding Extracellular Vesicle Crosstalk in Tumor Microenvironments
Imagine a crowded party where people pass notes. Cells do this too, but instead of paper notes, they send tiny membrane-bound packages called extracellular vesicles (EVs). These EVs are like postal parcels filled with proteins, lipids, and snippets of RNA. They are released by virtually every cell type, including cancer cells. In the tumor microenvironment—the surrounding tissue that includes blood vessels, immune cells, and connective tissue—these EVs act as an intercellular communication system. When a cancer cell releases an EV, it can be taken up by a neighbor, like a macrophage or a fibroblast, and deliver its cargo to alter that cell's behavior. This is called crosstalk: a bidirectional conversation using EVs as couriers. This communication helps the tumor survive, grow, and even spread.
A deeper explanation
The mechanism of EV-mediated crosstalk is both subtle and powerful. EVs are classified broadly into exosomes (formed inside cells) and microvesicles (budding from the cell membrane). They contain a lipid bilayer that protects their cargo from degradation. When an EV fuses with a target cell, it releases its contents—mRNAs, microRNAs, and proteins—that can reprogram the recipient cell's gene expression. In the tumor microenvironment, tumor-derived EVs can suppress immune responses by delivering molecules that make immune cells less aggressive, or they can activate tumor-associated fibroblasts to form a supportive stroma. EVs also promote angiogenesis by carrying growth factors and RNA to endothelial cells. Critically, certain EVs called oncosomes can carry oncogenic proteins, and some are able to travel through the bloodstream to distant sites, creating a 'pre-metastatic niche' by altering the local environment before cancer cells even arrive. This is why EVs are not just bystanders but active participants in cancer progression.